After years of patent protection, biosimilars for Humira are set to enter the US market in 2023. The arrival of these drugs has been widely anticipated throughout the healthcare industry.

AbbVie’s promising pipeline and 3.95% dividend yield offer growth potential. Read why ABBV stock could thrive despite the Emraclidine trial failure.

For the first time, pharmacists in the US will be able to substitute a cheaper biosimilar version when they receive a prescription for AbbVie’s high-concentration formulation of Humira ...

ABBV stock has seen strong gains of 85% from levels of $90 in early January 2021 to around $165 now, vs. an increase of about ...

AbbVie’s high dividend yield and leadership with Skyrizi and Rinvoq make it a top pick. Learn why ABBV stock is a strong buy ...

Earlier this month, the S&P 500 hit a record high of more than 6,000 for the first time ever. Based on that, you might assume ...

Dividend stocks provide investors with reliable passive income. These four health care picks look like outstanding ideas now.

Scottsdale resident Robin Brody was running marathons and raising funds for the Leukemia & Lymphoma Society when her son, ...

Seniors in metro Detroit and across Michigan have an opportunity to sign up for the right Medicare plan during open ...

Notable news about inflammatory bowel disease (IBD) in 2024 included a study evaluating loss of response to tumor necrosis ...

We recently published a list of 8 Most Promising Healthcare Stocks According to Hedge Funds. In this article, we are going to ...

For more information on fire danger ratings and actions refer to www.cfa.vic.gov.au Note: On occasion Fire Danger Ratings may not adhere to FBI thresholds above due to agency discretion in setting ...